Alphatec Holdings, Inc. Adds Bone Growth Stimulator to Spinal Product Line
11 Juli 2006 - 2:30PM
PR Newswire (US)
Signs Private Label Distribution Agreement With IsoTis for
Demineralized Bone Matrix Products CARLSBAD, Calif., July 11
/PRNewswire-FirstCall/ -- Alphatec Holdings, Inc. (NASDAQ:ATEC), a
medical device company that provides customized spinal products and
a broad suite of spine fusion solutions, announced today that it
has signed a private label distribution agreement with IsoTis
OrthoBiologics (SWX/Euronext: ISON; TSX: ISO) for distribution of
IsoTis's demineralized bone matrix ("DBM") products under
Alphatec's brand name. These well-established DBM products,
currently sold under the IsoTis brand names of DynaGraft(R) II and
OrthoBlast(R) II, have osteo-inductive properties which stimulate
new bone formation and can be used in combination with traditional
spinal implants to stabilize the spine following spine fusion
procedures. Under the agreement, which has certain minimum order
quantity requirements, Alphatec has placed an initial order that
should allow for commercial sale through Alphatec's distribution
base by the fourth quarter of this year. "Many patients who undergo
surgery using Alphatec's high quality spinal screws and spacers can
benefit from the use of IsoTis's DBM products," said Ronald G.
Hiscock, President and Chief Executive Officer of Alphatec.
"Surgeons who might have looked to other vendors for this product
will now be able to use Alphatec's own private label brand. This
addition to our product line is an ideal complement and one that
allows us to better serve our surgeon's total requirements while
limiting their need to look elsewhere." Hiscock added, "This
agreement demonstrates again our commitment to providing a full
breadth of product to serve the needs of the spinal fusion
marketplace. Alphatec has moved aggressively to expand its product
portfolio to include both new technologies and, importantly, many
product alternatives that meet the diverse needs of the surgeon
community. Because other DBM's are being used today with Alphatec's
products, we believe that the potential exists to quickly
assimilate a new, branded Alphatec DBM into our mix of surgeries,
thereby increasing revenue per surgery." About Alphatec Alphatec is
a medical device company focused on the design, development,
manufacturing and marketing of products for the surgical treatment
of spine disorders. Alphatec's principal product offering is
primarily focused on the estimated $2.2 billion U.S. spine fusion
market through its wholly-owned subsidiary, Alphatec Spine, Inc.,
and includes a variety of spinal implant products and systems
comprised of components such as spine screws, spinal spacers, and
plates that offer multiple solutions to address patients' needs. In
addition to Alphatec's U.S. presence, it also participates in the
Japanese spine fusion and orthopedic trauma markets through its
subsidiary, Alphatec Pacific, Inc. Our mission is to be a value
based leader in the spinal market by providing unmatched service to
and taking scientific direction from our physician customers. We do
so through our unique in-house manufacturing facility in Carlsbad,
California that allows us to respond quickly and to customize
innovative products needed for spine fusion surgery. About IsoTis
IsoTis OrthoBiologics has a product portfolio with several
innovative and proprietary natural and synthetic bone graft
substitutes on the market and others in development, an established
North American independent distribution network, and an expanding
international presence. The company's main commercial operations
are based out of Irvine, CA; its international sales headquarters
is based in Lausanne, Switzerland. Forward Looking Statements This
press release may contain forward-looking statements that involve
risks and uncertainty, including statements that Alphatec's
commercial sale of such private label DBM products will occur in
the fourth quarter of 2006, that many of Alphatec's surgeries are
candidates for use with a DBM product, that surgeons will adopt our
private label DBM products, and that our private label DBM products
will provide complementary revenues by increasing our revenue per
surgery. Such statements are based on management's current
expectations and are subject to a number of risks and uncertainties
that could cause actual results to differ materially from those
described in the forward-looking statements. Alphatec cautions
investors that there can be no assurance that actual results or
business conditions will not differ materially from those projected
or suggested in such forward-looking statements as a result of
various factors, including, but not limited to, the following:
Alphatec's ability to develop and expand its spine fusion business
in the United States and Japan, Alphatec's ability to expand and
maintain a successful sales and marketing organization,
continuation of favorable third party payor reimbursement for
procedures performed using our products, unanticipated expenses or
liabilities or other adverse events affecting cash flow or
Alphatec's ability to achieve profitability, uncertainty of
additional funding, uncertainty of success in developing any new
products, failure to successfully introduce and develop new
products, including products related to the dynamic cervical plate
license agreement and the other license agreements, failure to
obtain FDA clearance or approval for particular devices, Alphatec's
ability to compete with other competing products and with emerging
new technologies within and outside of spinal fusion, product
liability exposure and patent infringement claims. Please refer to
the risks detailed in Alphatec's Form S-1 on file with the SEC, as
well as the risks detailed from time to time in Alphatec's SEC
reports, including quarterly reports on Form 10-Q, reports on Form
8-K and annual reports on Form 10-K. We disclaim any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events, or
otherwise, unless required by law. DATASOURCE: Alphatec Holdings,
Inc. CONTACT: Investors, Matt Clawson of Allen & Caron, Inc.,
+1-949-474-4300, , for Alphatec Holdings, Inc.; or Stephen T. D.
Dixon, Vice President and CFO of Alphatec Holdings, Inc.,
+1-760-431-9286
Copyright
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
Von Jul 2023 bis Jul 2024